Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
New guidance coming soon!
-
Coming soon!! New guidance from PAAB stemming from our global benchmarking initiative.
@Agency @Manufacturer The consultation process for guidance on clinical trials whose duration exceeds that of the pivotal trials in the TMA is winding down. Please stay tuned for the publication of the guidance later this month with projected implementation in April.
We look forward to answering all your questions once we’ve published a guidance.
